FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling 
Trump Orders Federal Agencies to Halt Use of Anthropic AI Technology 
USITC to Review Impact of Revoking China’s PNTR Status, Potentially Raising Tariffs on Chinese Imports 
U.S.-Canada Trade Talks Resume as Trump Administration Reviews USMCA 
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Bank of Korea Holds Interest Rate at 2.50% as Growth Outlook Improves Amid AI Chip Boom 
Gold Prices Rebound as U.S. Tariffs, Fed Policy and Iran Talks Drive Market Sentiment 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
BOJ Signals Possible April Rate Hike as Ueda Eyes Inflation and Wage Growth Data 
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline 
OpenAI Hires Former Meta and Apple AI Leader Ruomin Pang Amid Intensifying AI Talent War 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
Oil Prices Steady as US-Iran Nuclear Talks and Rising Crude Inventories Shape Market Outlook 
Toyota Plans $19 Billion Share Sale in Major Corporate Governance Reform Move 
BlueScope Steel Shares Drop After Rejecting Revised A$15 Billion Takeover Bid 
Gold Prices Rally in February as Geopolitical Risks and Economic Uncertainty Boost Safe-Haven Demand 
U.S. Stock Futures Fall as Nvidia Drops Despite Strong Earnings; Netflix Jumps 9% 
Reckitt Benckiser announced last weekend that it is selling its Mead Johnson Nutrition company in China to Primavera Capital Group. The deal was said to be valued at $2.2 billion.
As per Reuters, while Primavera Capital has already bought Reckitt Benckiser’s infant formula and child nutrition business in China, the latter will still retain an eight percent stake in the China unit of Mead Johnson Nutrition.
Reckitt to incur a loss on the sale
Reckitt Benckiser is expecting to receive around $1.3 billion from the sale, but it is also anticipating a net loss of $3.5 billion on the disposal. The loss is said to be due to intangible assets and re-measurement of goodwill.
In any case, it was in March when it was first reported that Reckitt Benckiser was considering the sale of the Chinese unit of Mead Johnson. The company observed a sluggish sale and launched a strategic review of its infant formula and child nutrition business in China.
In the end, the sale was decided as sales are not going up anywhere, and Reckitt cited the intense competition with local baby formula brands as one of the reasons for the slow income. Also, the low birth rates in China was also blamed for the dwindling sales as there are fewer babies to feed with the infant formula.
The deal between Reckitt and Primavera
As the sale was revealed, Reckitt Beckinser shared that the deal with Primavera Capital includes the sale of the company’s production factories in Guangzhou, China, and at Nijmegen in the Netherlands. Moreover, a royalty-free perpetual and exclusive license of Mead Johnson and Enfa brands in China, including Enfagrow, Enfamil, and Enfinitas, are also included in the agreement.
Then again, it should be noted that this is only in Greater China, as Reckitt still owns and will continue to sell Mead Johnson and Enfa products in other parts of the world.
"We are pleased to acquire the Greater China business of Mead Johnson, a long-established and renowned multinational infant and children nutrition brand,” Primavera Capital Group founder and chairman, Dr. Fred Hu, said in a press release. “As the controlling shareholder, Primavera is committed to serve tens of millions of Chinese mothers and babies and safeguard their well-being.”
Finally, the Reckitt Beckinser and Primavera Capital deal is expected to close within the second half of this year.
